realitycheck4u wrote: I tried to inform some people of the current state of TH by describing things this way. Did I explain this well?
_____
We will be hearing results of whether TH1902 is safe soon - and we may or may not hear about efficacy at the same time. Likely not, as that is phase 1b and we are in phase 1a. Anyhow, if we find out it is safe, we move to 1b. If not, we’re screwed. I am betting it is safe. So let’s assume that and go deeper. Here is my “Sunday Summary” and unscientific explanation of where TH is headed. The current trial is to prove that TH1902 can find a Sortilin expressing cancer cell, get sucked into it, and release the drug. If Phase 1a and 1b proves the concept actually works, that’s big. Huge actually. But, that’s not the total solution to killing all cancer cells in a patient. It will only help - and would save lives. But it’s not a final solution because there are cancer cells which are not expressing Sortilin. TH1902 can’t find them. TH thinks they have an answer for that - and they have alluded to this a few times. I will explain. Once they know TH1902 is safe, they will move to phase 1b to learn about how well it works (super important obviously) and that will take 6 to 9 months before results are released. At the same time though, they are going try to further enhance the targeting of TH1902 by incorporating a patients own Genes into the makeup of a patient specific TH1902. Essentially, rather than just target Sortilin, it could make an siRNA TH1902 version which has the benefit of silencing some genes and allow better targeting to the cancer cell, and better internalization of TH1902 and the killing agent. It could be ANY killing agent too (that’s a bonus I will not get into). And shocking TH have already announced the hiring of people with siRNA experience already. Why would TH do this?? Well they think TH1902 works only on Sortilin expressing cancer cells, BUT, if they can also add a siRNA (small interfering RNA) targeting agent, then this would mean that TH1902 could better distinguish between (1) a cancer call expressing Sortilin (which in what they are trying to prove works) and other cancer cells in the body not expressing Sortilin. The fact is that a person will have both types of cancer cells at the same time and this depends on the type of Cancer, and the person themselves. Breast cancer can have 60% or 80% Sortilin expressing cells. What about the other 20-40%? The reality is that cells not expressing Sortilin cannot be targeted by TH1902 alone as there is nothing to connect TH1902 with. However, if TH1902 works (by being internalized to release the payload inside of a cancer cell), then the final piece of the puzzle is to make the targeting agent even better. In comes siRNA targeting bundled with TH1902. What scientists and drug companies know now is that a way to do it would be to target cancer cells by knowing what a healthy cell in that exact person LOOKS LIKE and silo cells some genes to allow better targeting. So, by combining TH1902 and using siRNA successfully to make it targeted even better, you would potentially have a something beyond incredible.
Lastly, somehow, TH1902 works on mice really well (proven on hundreds of real mice, not in theory), so if all else fails, we will just wait a bit longer until Trudeau starts a CERB program for mice (with billions in cash no doubt) and TH will just sell the drug to the mice .